Jesper Kløve from Novo Nordisk succeeds Morten Nielsen as CEO in the pharma engineering company NNE Pharmaplan. The change is a consequence of Novo Nordisk’s planned investment in a new diabetes API plant in USA.
NNE Pharmaplan’s present chief executive officer Morten Nielsen has decided to leave the position in order to move to North Carolina, USA, and manage Novo Nordisk’s large investment project in a new diabetes API plant, filling the position of Project Director and Senior Vice President for diabetes API in USA.
Jesper Kløve thus takes up the position as new CEO of the Novo Nordisk-owned engineering company NNE Pharmaplan as of 1 September 2015. Jesper Kløve is 49 years old and comes from a position at Novo Nordisk as Senior Vice President of Device R&D where he has been responsible for research and development of the entire portfolio of devices since 2008. He has been employed at Novo Nordisk since 2003 and has held various management positions in the Novo group.
”Jesper Kløve is a strong man in the position as new CEO of NNE Pharmaplan,” says Lars Fruergaard Jørgensen, chairman of NNE Pharmaplan’s board of directors and Executive Vice President at Novo Nordisk. ”Jesper Kløve has many years of management experience from global companies and has brought about significant results within the area of devices at Novo Nordisk where he secured the launching of the insulin pens FlexTouch® and NovoPen® 5 and established a strong portfolio of new device units.”
Lars Fruergaard Jørgensen concludes: ”I would like to thank Morten Nielsen for the very positive development that NNE Pharmaplan has gone through under his leadership since 2011. Morten succeeded in cementing NNE Pharmaplan as a stable and profitable business and he has strengthened the company’s customer focus. Today, NNE Pharmaplan is positioned as one of the leading pharma engineering companies serving the largest pharmaceutical businesses in the world. Jesper Kløve’s task is now to continue the further business development.”